Franklin Genomic Advancements ETF (BATS:HELX) Stock Short Interest Report for September

Franklin Genomic Advancements ETF (BATS:HELX) was the target of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totaling 367 shares, a decrease of 82.1% from the September 15th total of 2,051 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily volume of 11,494 shares, the short-interest ratio is currently 0.0 days.

Franklin Genomic Advancements ETF Price Performance

Shares of BATS:HELX opened at $42.64 on Monday. Franklin Genomic Advancements ETF has a 12-month low of $31.24 and a 12-month high of $45.58. The firm has a market cap of $17.06 million, a P/E ratio of 26.71 and a beta of 1.05. The business has a fifty day simple moving average of $42.26 and a 200 day simple moving average of $38.07.

Franklin Genomic Advancements ETF Company Profile

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.